Retroperitoneal Fibrosis Secondary to Tuberculosis and Sigmoid Colon Cancer: Two Case Reports Presenting with Acute Obstructive Renal Failure and a Review of the Literature
Retroperitoneal fibrosis is a rare condition, with an estimated incidence between 1 in 200,000 and 1 in 500,000 per year, characterized by the proliferation of fibrous tissue in the retroperitoneal space, which can compress the ureters and cause acute obstructive renal failure. It may be idiopathic or secondary to various causes, including infections such as tuberculosis or malignancies such as sigmoid colon cancer. We report two distinct cases: a 42-year-old woman with tuberculous retroperitoneal fibrosis presenting with low back pain and anuria, successfully treated with corticosteroids and antituberculosis therapy; and a 25-year-old man with post-surgical retroperitoneal fibrosis secondary to sigmoid adenocarcinoma, who progressed to chronic renal failure despite oncologic management. A review of the literature indicates that these secondary forms, although rare, involve inflammatory (tuberculosis) or desmoplastic (cancer) mechanisms. Diagnosis is based on imaging (ultrasound, CT scan, magnetic resonance imaging), and treatment is guided by the underlying etiology. These cases highlight the importance of a multidisciplinary approach to determine the cause and optimize outcomes.
References
[1]
Vaglio, A., Salvarani, C. and Buzio, C. (2006) Retroperitoneal Fibrosis. The Lancet, 367, 241-251. https://doi.org/10.1016/s0140-6736(06)68035-5
[2]
WHO (2022) Global Tuberculosis Report. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2022
[3]
Sharma, S.K. and Mohan, A. (2004) Extrapulmonary Tuberculosis. Indian Journal of Medical Research, 120, 316-353.
[4]
Maghraoui, A., Ammouri, W., Bouiga, N., Bourkia, M., Khibri, H., Mouatassim, N., et al. (2018) Profil clinique, thérapeutique et évolutif des fibroses rétropéritonéales de l’adulte. La Revue de Médecine Interne, 39, A147-A148. https://doi.org/10.1016/j.revmed.2018.10.093
[5]
Jakhlal, N., Elghazoui, A., Jabbour, Y., Karmouni, T., Elkhader, K., Koutani, A., et al. (2017) Fibrose rétropéritonéale: Revue de littérature. Canadian Urological Association Journal, 11, 26-31. https://doi.org/10.5489/cuaj.4122
[6]
van Bommel, E.F.H., Jansen, I., Hendriksz, T.R. and Aarnoudse, A.L.H.J. (2009) Idiopathic Retroperitoneal Fibrosis. Medicine, 88, 193-201. https://doi.org/10.1097/md.0b013e3181afc420
[7]
Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. https://doi.org/10.3322/caac.21590
[8]
Mitchinson, M.J. (1970) The Pathology of Idiopathic Retroperitoneal Fibrosis. Journal of Clinical Pathology, 23, 681-689. https://doi.org/10.1136/jcp.23.8.681
[9]
Wynn, T.A. and Ramalingam, T.R. (2012) Mechanisms of Fibrosis: Therapeutic Translation for Fibrotic Disease. Nature Medicine, 18, 1028-1040. https://doi.org/10.1038/nm.2807
[10]
De Wever, O. and Mareel, M. (2003) Role of Tissue Stroma in Cancer Cell Invasion. The Journal of Pathology, 200, 429-447. https://doi.org/10.1002/path.1398
[11]
Levental, K.R., Yu, H., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., et al. (2009) Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling. Cell, 139, 891-906. https://doi.org/10.1016/j.cell.2009.10.027
[12]
El Mansouri, Y., Benchekroun, A., Nouini, Y., et al. (2002) Fibrose rétropéritonéale et tuberculose ganglionnaire abdominale. Discussion étiopathogénique. Annales d’Urologie, 36, 325-328.
[13]
Zhou, L., Liu, S., Han, M., et al. (2019) Retroperitoneal Fibrosis Associated with Malignancy: A Case Report and Review of the Literature. Journal of International Medical Research, 47, 3998-4004.
[14]
Treglia, G., Mattoli, M.V., Leccisotti, L., et al. (2014) Usefulness of 18F-FDG PET/CT in Retroperitoneal Fibrosis: A Case Series and Literature Review. Clinical Nuclear Medicine, 39, e383-e388.
[15]
Golden, M.P. and Vikram, H.R. (2005) Extrapulmonary Tuberculosis: An Overview. American Family Physician, 72, 1761-1768.
[16]
Vaglio, A., Palmisano, A., Alberici, F., Maggiore, U., Ferretti, S., Cobelli, R., et al. (2011) Prednisone versus Tamoxifen in Patients with Idiopathic Retroperitoneal Fibrosis: An Open-Label Randomised Controlled Trial. The Lancet, 378, 338-346. https://doi.org/10.1016/s0140-6736(11)60934-3